S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

MRK Merck and Co Inc

109.69

-0.04 (-0.04%)

Oct 14 2024 - Closed

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2024 to Oct 2024

Click Here for more Merck Charts.

Merck (NYSE:MRK)
Historical Stock Chart
From Oct 2023 to Oct 2024

Click Here for more Merck Charts.

Merck and Co Inc News

Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
Monday 14 October 2024 (12 hours ago) • Business Wire

New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio
Wednesday 9 October 2024 (6 days ago) • Business Wire

Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma
Tuesday 8 October 2024 (7 days ago) • Business Wire

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More
Thursday 3 October 2024 (2 weeks ago) • InvestorsHub NewsWire

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More
Thursday 3 October 2024 (2 weeks ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 1 October 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 1 October 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 1 October 2024 (2 weeks ago) • Edgar (US Regulatory)

Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
Tuesday 1 October 2024 (2 weeks ago) • Business Wire

Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
Tuesday 1 October 2024 (2 weeks ago) • Business Wire

Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
Thursday 26 September 2024 (3 weeks ago) • Business Wire

Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
Wednesday 25 September 2024 (3 weeks ago) • Business Wire

More Merck and Co Inc News Articles

Geopulse Explorations (PK)

Kraig Biocraft Laborator... (QB)

Voip Pal Com (QB)

Trump Media and Technology

Lehman Brothers Financial (CE)

Fannie Mae (QB)

TPT Global Tech (PK)

Verb Technology

Valiant Eagle (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions